Symbio   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Jose CA United States (1994)

Organization Overview

First Clinical Trial
2012
NCT01580878
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

http://symbioresearch.com | http://symbioresearch.com/ | Symbio, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

phenazopyridine (gantanol) (1 trial)

Drugs in Phase 2 Trials (1)

mtc896 (1 trial)

Drugs in Phase 1 Trials (4)

benzoyl peroxide (clearasil) (1 trial)

butenafine (mentax) (1 trial)

clindamycin (cleocin) (1 trial)

mupirocin (bactroban) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 2)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Tinea (Phase 1)

Tinea Pedis (Phase 1)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 6